Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Andrology

Free Subscription Articles published in Prostate Retrieve available abstracts of 36 articles: HTML format

Single Articles

October 2022
1. JIN R, Forbes C, Miller NL, Strand D, et al
   Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
   Prostate. 2022;82:1378-1388.
   PubMed     Abstract available
   
   
   September 2022
2. BENGTSEN MB, Heide-Jorgensen U, Borre M, Knudsen JS, et al
   Acute urinary retention in men: 21-year trends in incidence, subsequent benign prostatic hyperplasia-related treatment and mortality: A Danish population-based cohort study.
   Prostate. 2022 Sep 20. doi: 10.1002/pros.24440.
   PubMed     Abstract available
   
   
   
3. SEVIM M, Alkis O, Kartal IG, Coser S, et al
   Impact of COVID-19 on the progression of benign prostatic hyperplasia and aggravation of related symptoms: A prospective study.
   Prostate. 2022 Sep 8. doi: 10.1002/pros.24439.
   PubMed     Abstract available
   
   
   
4. JIA L, Strand DW, Goueli RS, Gahan JC, et al
   PSA density is associated with BPH cellular composition.
   Prostate. 2022;82:1162-1169.
   PubMed     Abstract available
   
   
   
5. HUA X, Zhang J, Ge S, Liu H, et al
   CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation.
   Prostate. 2022;82:1223-1236.
   PubMed     Abstract available
   
   
   May 2022
6. ASKER H, Yilmaz-Oral D, Oztekin CV, Gur S, et al
   An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.
   Prostate. 2022 May 17. doi: 10.1002/pros.24366.
   PubMed     Abstract available
   
   
   
7. ZHANG M, Jin C, Kong X, Meng J, et al
   Identification of novel susceptibility factors related to CP/CPPS-like symptoms: Evidence from a multicenter case-control study.
   Prostate. 2022;82:772-782.
   PubMed     Abstract available
   
   
   
8. MOROZOV A, Bazarkin A, Babaevskaya D, Taratkin M, et al
   A systematic review and meta-analysis of placebo effect in clinical trials on chronic prostatitis/chronic pelvic pain syndrome.
   Prostate. 2022;82:633-656.
   PubMed     Abstract available
   
   
   February 2022
9. STAMIS SA, Heath EI, Lucas S, Boerner J, et al
   Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
   Prostate. 2022 Feb 8. doi: 10.1002/pros.24310.
   PubMed     Abstract available
   
   
   
10. DROGHETTI M, Porreca A, Bianchi L, Piazza P, et al
    Long-term outcomes of Holmium laser enucleation of prostate and predictive model for symptom recurrence.
    Prostate. 2022;82:203-209.
    PubMed     Abstract available
    
    
    January 2022
11. HUANG R, Liu Y, Li B, Wang R, et al
    Inhibition of human prostate smooth muscle contraction by the inhibitors of protein kinase C, GF109203X, and Go6983.
    Prostate. 2022;82:59-77.
    PubMed     Abstract available
    
    
    
12. KIM SW, Lee J, Oh S, Son H, et al
    Restoration of erectile function by a combination of antiapoptosis by JNK inhibitor and preservation of smooth muscle or endothelium by hepatocyte growth factor in a rat model of cavernous nerve injury.
    Prostate. 2022;82:49-58.
    PubMed     Abstract available
    
    
    December 2021
13. IGARASHI T, Tyagi P, Mizoguchi S, Saito T, et al
    Therapeutic effects of nerve growth factor-targeting therapy on bladder overactivity in rats with prostatic inflammation.
    Prostate. 2021;81:1303-1309.
    PubMed     Abstract available
    
    
    November 2021
14. CHEN J, Zhang LG, Du HX, Zhan CS, et al
    Melatonin attenuates prostatic inflammation and pelvic pain via Sirt1-dependent inhibition of the NLRP3 inflammasome in an EAP mouse model.
    Prostate. 2021;81:1179-1190.
    PubMed     Abstract available
    
    
    October 2021
15. CHEN J, Meng J, Jin C, Mo F, et al
    4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy for chronic prostatitis.
    Prostate. 2021;81:1078-1090.
    PubMed     Abstract available
    
    
    September 2021
16. LIU D, Liu J, Li Y, Liu H, et al
    Upregulated bone morphogenetic protein 5 enhances proliferation and epithelial-mesenchymal transition process in benign prostatic hyperplasia via BMP/Smad signaling pathway.
    Prostate. 2021 Sep 23. doi: 10.1002/pros.24241.
    PubMed     Abstract available
    
    
    
17. CASTRO NFDC, Jubilato FC, Guerra LHA, Santos FCAD, et al
    Therapeutic effects of beta-caryophyllene on proliferative disorders and inflammation of the gerbil prostate.
    Prostate. 2021;81:812-824.
    PubMed     Abstract available
    
    
    
18. INES M, Babar M, Singh S, Iqbal N, et al
    Real-world evidence with The Rezum System: A retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes.
    Prostate. 2021;81:956-970.
    PubMed     Abstract available
    
    
    August 2021
19. LIAO G, Lee PMY, Zhao S, Ho WM, et al
    Joint effect between bisphenol A and alcohol consumption on benign prostatic hyperplasia: A case-control study in Hong Kong Chinese males.
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24217.
    PubMed     Abstract available
    
    
    
20. LI Y, Wang Q, Li J, Shi B, et al
    SIRT3 affects mitochondrial metabolic reprogramming via the AMPK-PGC-1alpha axis in the development of benign prostatic hyperplasia.
    Prostate. 2021 Aug 19. doi: 10.1002/pros.24208.
    PubMed     Abstract available
    
    
    July 2021
21. JIN R, Strand DW, Forbes CM, Case T, et al
    The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Prostate. 2021 Jul 20. doi: 10.1002/pros.24190.
    PubMed     Abstract available
    
    
    
22. BASSILY D, Wong V, Phillips JL, Fraiman M, et al
    Rezum for retention-retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia.
    Prostate. 2021 Jul 20. doi: 10.1002/pros.24201.
    PubMed     Abstract available
    
    
    June 2021
23. MYKONIATIS I, Pyrgidis N, Kalyvianakis D, Zilotis F, et al
    Comparing two different low-intensity shockwave therapy frequency protocols for nonbacterial chronic prostatitis/chronic pelvic pain syndrome: A two-arm, parallel-group randomized controlled trial.
    Prostate. 2021;81:499-507.
    PubMed     Abstract available
    
    
    
24. QIAN Q, He W, Liu D, Yin J, et al
    M2a macrophage can rescue proliferation and gene expression of benign prostate hyperplasia epithelial and stroma cells from insulin-like growth factor 1 knockdown.
    Prostate. 2021;81:530-542.
    PubMed     Abstract available
    
    
    April 2021
25. QIAN S, Zhang S, Xia W, Xu D, et al
    Correlation of prostatic morphological parameters and clinical progression in aging Chinese men with benign prostatic hyperplasia: Results from a cross-sectional study.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24128.
    PubMed     Abstract available
    
    
    March 2021
26. AYDOGDU O, Gocun PU, Aronsson P, Carlsson T, et al
    Prostate-to-bladder cross-sensitization in a model of zymosan-induced chronic pelvic pain syndrome in rats.
    Prostate. 2021;81:252-260.
    PubMed     Abstract available
    
    
    January 2021
27. LIU Y, Zhang Y, Zhang M, Meng J, et al
    Activated autophagy restored the impaired frequency and function of regulatory T cells in chronic prostatitis.
    Prostate. 2021;81:29-40.
    PubMed     Abstract available
    
    
    December 2020
28. ZHANG LG, Yu ZQ, Yang C, Chen J, et al
    Effect of Eriocalyxin B on prostatic inflammation and pelvic pain in a mouse model of experimental autoimmune prostatitis.
    Prostate. 2020;80:1394-1404.
    PubMed     Abstract available
    
    
    
29. MIZOGUCHI S, Mori K, Shin T, Wang Z, et al
    Effects of dutasteride in a rat model of chemically induced prostatic inflammation-Potential role of estrogen receptor beta.
    Prostate. 2020;80:1413-1420.
    PubMed     Abstract available
    
    
    November 2020
30. JAIN S, Samal AG, Das B, Pradhan B, et al
    Escherichia coli, a common constituent of benign prostate hyperplasia-associated microbiota induces inflammation and DNA damage in prostate epithelial cells.
    Prostate. 2020;80:1341-1352.
    PubMed     Abstract available
    
    
    
31. GAT Y, Joshua S, Vuk-Pavlovic S, Goren M, et al
    Paying the price for standing tall: Fluid mechanics of prostate pathology.
    Prostate. 2020;80:1297-1303.
    PubMed     Abstract available
    
    
    October 2020
32. WANG K, Pascal LE, Li F, Chen W, et al
    Tight junction protein claudin-1 is downregulated by TGF-beta1 via MEK signaling in benign prostatic epithelial cells.
    Prostate. 2020;80:1203-1215.
    PubMed     Abstract available
    
    
    
33. CHEN W, Pascal LE, Wang K, Dhir R, et al
    Differential impact of paired patient-derived BPH and normal adjacent stromal cells on benign prostatic epithelial cell growth in 3D culture.
    Prostate. 2020;80:1177-1187.
    PubMed     Abstract available
    
    
    September 2020
34. EPSTEIN DJ, Thompson LDR, Saleem A, Kao CS, et al
    Fungal prostatitis due to endemic mycoses and Cryptococcus: A multicenter case series.
    Prostate. 2020;80:1006-1011.
    PubMed     Abstract available
    
    
    
35. PENG X, Guo H, Chen J, Wang J, et al
    The effect of pirfenidone on rat chronic prostatitis/chronic pelvic pain syndrome and its mechanisms.
    Prostate. 2020;80:917-925.
    PubMed     Abstract available
    
    
    
36. SMITH DK, Hasanali SL, Wang J, Kallifatidis G, et al
    Promotion of epithelial hyperplasia by interleukin-8-CXCR axis in human prostate.
    Prostate. 2020;80:938-949.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Andrology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: